Abilify (aripiprazole) is the first atypical antipsychotic approved for ADD-ON therapy for depression
September 2013
Abilify (aripiprazole) is the first atypical antipsychotic approved for ADD-ON therapy for depression.
Seroquel XR (quetiapine) is already approved for MONOTHERAPY for depression when other antidepressants fail.
Up to two-thirds of patients with depression still have symptoms despite an adequate trial of an antidepressant.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive